
AZD9291
收藏
分享
- ¥500 - 800
- 自有
- 上海
- SYSBC014
- 2025年07月08日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 保质期:
2年
- 英文名:
(Mereletinib mesylate; EGFR inhibitor; AZD9291 mesylate; AZD 9291 mesylate)
- 库存:
1kg 库存
- 曾用名:
(Mereletinib mesylate; EGFR inhibitor; AZD9291 mesylate; AZD 9291 mesylate)
- 产品用途:
肺癌
- 规格:
99%
| 英文名 | AZD-9291 mesylate | |
| 别名 | N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1) | |
| 产品名称 | AZD-9291 甲磺酸盐 | |
| 分子结构 | ||
| 分子式 | C28H33N7O2.CH4O3S | |
| 分子量 | 595.71 | |
| CAS 登录号 | 1421373-66-1 | |
AZD-9291 mesylate的生物活性
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).IC50 value: 12.92 nM(Exon 19 deletion EGFR); 11.44 nM(L858R/T790M EGFR) [1]
Target: L858R/T790M EGFR; Exon 19 deletion EGFR
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines.
Patent: WO 2013014448
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验相关实验
为什么你的 qPCR 重复性差?灵敏度低?扩增易受抑制?那是你还不知道数字 PCR
for copy number analysis of the CCL4L genes." Infection, Genetics and Evolution 25 (2014): 28 - 35.4.Oxnard, Geoffrey R., et al. "Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung
技术资料暂无技术资料 索取技术资料
AZD9291
¥500 - 800







